[HTML][HTML] Million Veteran Program: A mega-biobank to study genetic influences on health and disease
Journal of clinical epidemiology, 2016•Elsevier
Objective To describe the design and ongoing conduct of the Million Veteran Program
(MVP), as an observational cohort study and mega-biobank in the Department of Veterans
Affairs (VA) health care system. Study Design and Setting Data are being collected from
participants using questionnaires, the VA electronic health record, and a blood sample for
genomic and other testing. Several ongoing projects are linked to MVP, both as peer-
reviewed research studies and as activities to help develop an infrastructure for future, broad …
(MVP), as an observational cohort study and mega-biobank in the Department of Veterans
Affairs (VA) health care system. Study Design and Setting Data are being collected from
participants using questionnaires, the VA electronic health record, and a blood sample for
genomic and other testing. Several ongoing projects are linked to MVP, both as peer-
reviewed research studies and as activities to help develop an infrastructure for future, broad …
Objective
To describe the design and ongoing conduct of the Million Veteran Program (MVP), as an observational cohort study and mega-biobank in the Department of Veterans Affairs (VA) health care system.
Study Design and Setting
Data are being collected from participants using questionnaires, the VA electronic health record, and a blood sample for genomic and other testing. Several ongoing projects are linked to MVP, both as peer-reviewed research studies and as activities to help develop an infrastructure for future, broad-based research uses.
Results
Formal planning for MVP commenced in 2009; the protocol was approved in 2010, and enrollment began in 2011. As of August 3, 2015, and with a steady state of ≈50 recruiting sites nationwide, N = 397,104 veterans have been enrolled. Among N = 199,348 with currently available genotyping data, most participants (as expected) are male (92.0%) between the ages of 50 and 69 years (55.0%). On the basis of self-reported race, white (77.2%) and African American (13.5%) populations are well represented.
Conclusions
By helping to promote the future integration of genetic testing in health care delivery, including clinical decision making, the MVP is designed to contribute to the development of precision medicine.
Elsevier